Inga Malinina

Inga Malinina has worked in a variety of roles in the scientific field since 1990. Inga began as a Graduate Research Assistant at Ivanovskii D.I. Institute of Virology in Moscow, Russia in 1990. Inga then became a Physician-Bacteriologist at Fryazino City Hospital in Russia in 1997, followed by a Research Technician III at UNC-CH Chapel Hill, NC in 2000. In 2000, they also began working as a Research Assistant at Princeton University, where they studied the mechanisms of sensory processing in chemotaxis. In 2006, they became a Research Associate at Novo Nordisk, where they studied the role of factor FXIII in prevention of multiple organ dysfunctions after burn injury and trauma-hemorrhagic shock. In 2008, they began working as a Research Scientist at Vaxinnate, where they studied the immunogenecity of hemaglutinin (HA) globular head-flagellin fusion proteins for vaccine development. In 2010, they began working as a Research Scientist at Merck, where they evaluated the impact of both manufacturing processes and materials on the properties of the biopharmaceutical bulk supply. Finally, in 2010, they began working as a Research Scientist at Advaxis, Inc., where they developed and tested anticancer vaccines based on attenuated Listeria monocytogenes.

Inga Malinina attended Russian State Medical University, Moscow from 1981 to 1989, where they earned a Master of Science (MS) in Medical Biophisics. Inga then obtained a Master of Science (MS) in Drug Discovery Research and Vaccine Development from the Russian Federation.